Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2026-04-14 @ 4:49 AM
Study NCT ID:
NCT00672334
Status:
TERMINATED
Last Update Posted:
2012-08-01
First Post:
2008-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sodium Bicarbonate in Cardiac Surgery Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['United States']}, 'interventionBrowseModule': {'meshes': [{'id': 'D017693', 'term': 'Sodium Bicarbonate'}, {'id': 'D012965', 'term': 'Sodium Chloride'}], 'ancestors': [{'id': 'D001639', 'term': 'Bicarbonates'}, {'id': 'D002254', 'term': 'Carbonates'}, {'id': 'D002255', 'term': 'Carbonic Acid'}, {'id': 'D017554', 'term': 'Carbon Compounds, Inorganic'}, {'id': 'D007287', 'term': 'Inorganic Chemicals'}, {'id': 'D017670', 'term': 'Sodium Compounds'}, {'id': 'D002712', 'term': 'Chlorides'}, {'id': 'D006851', 'term': 'Hydrochloric Acid'}, {'id': 'D017606', 'term': 'Chlorine Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2', 'PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 350}}, 'statusModule': {'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2008-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-07', 'completionDateStruct': {'date': '2012-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-07-31', 'studyFirstSubmitDate': '2008-05-01', 'studyFirstSubmitQcDate': '2008-05-01', 'lastUpdatePostDateStruct': {'date': '2012-08-01', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2008-05-06', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients developing an increase in serum creatinine > 25% or >44µmicromol/L from baseline to peak level after adjustment for relevant baseline characteristics', 'timeFrame': 'within first two-five postoperative days.'}], 'secondaryOutcomes': [{'measure': 'Proportion of patients developing an increase in serum creatinine greater than 50% from baseline to peak level after adjustment for relevant baseline characteristics', 'timeFrame': 'within first two-five postoperative days'}, {'measure': 'Proportion of patients developing an increase in serum creatinine greater than 100% from baseline to peak level after adjustment for relevant baseline characteristics', 'timeFrame': 'within first two-five postoperative days'}, {'measure': 'Change in serum creatinine from baseline to peak level after adjustment for relevant baseline characteristics', 'timeFrame': 'within first two-five postoperative days'}, {'measure': 'Proportion of patients developing any of the RIFLE criteria: R, I or F after adjustment for relevant baseline characteristics', 'timeFrame': 'within first five postoperative days'}, {'measure': 'Proportion of patients developing any of the AKI stages: 1, 2 or 3 (using network definition)after adjustment for relevant baseline characteristics', 'timeFrame': 'within 48 hours postoperatively'}, {'measure': 'Change in serum urea from baseline to peak', 'timeFrame': 'within first two-five postoperative days'}, {'measure': 'Change in NGAL from baseline to peak', 'timeFrame': 'within first 24 postoperatively'}, {'measure': 'Change in electrolyte status from baseline to peak', 'timeFrame': 'within first 24-48hrs postoperatively'}, {'measure': 'Requirement of renal replacement therapy', 'timeFrame': 'within first postoperative days'}, {'measure': 'Length of ventilation', 'timeFrame': 'from commencement to end of intubation'}, {'measure': 'Length of stay in Intensive care', 'timeFrame': 'from admission to discharge from Intensive care'}, {'measure': 'Length of stay in hospital', 'timeFrame': 'from admission to discharge from hospital'}, {'measure': 'Hospital-Mortality', 'timeFrame': 'during hospital stay'}, {'measure': '90-day mortality', 'timeFrame': 'during 90 days postoperatively'}, {'measure': 'COMT polymorphism', 'timeFrame': 'sampling at induction of anesthesia'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Cardiac surgery', 'Cardiopulmonary bypass', 'Oxidative stress', 'Acute renal dysfunction', 'Sodium bicarbonate'], 'conditions': ['Cardiac Surgery', 'Cardiopulmonary Bypass']}, 'referencesModule': {'references': [{'pmid': '34543256', 'type': 'DERIVED', 'citation': 'Elitok S, Kuppe H, Devarajan P, Bellomo R, Isermann B, Westphal S, Kube J, Albert C, Ernst M, Kropf S, Haase-Fielitz A, Haase M. Urinary Neutrophil Gelatinase-Associated Lipocalin/Hepcidin-25 Ratio for Early Identification of Patients at Risk for Renal Replacement Therapy After Cardiac Surgery: A Substudy of the BICARBONATE Trial. Anesth Analg. 2021 Dec 1;133(6):1510-1519. doi: 10.1213/ANE.0000000000005741.'}, {'pmid': '34028701', 'type': 'DERIVED', 'citation': 'Elitok S, Devarajan P, Bellomo R, Isermann B, Haase M, Haase-Fielitz A. NGAL/hepcidin-25 ratio and AKI subtypes in patients following cardiac surgery: a prospective observational study. J Nephrol. 2022 Mar;35(2):597-605. doi: 10.1007/s40620-021-01063-5. Epub 2021 May 24.'}, {'pmid': '23610561', 'type': 'DERIVED', 'citation': 'Haase M, Haase-Fielitz A, Plass M, Kuppe H, Hetzer R, Hannon C, Murray PT, Bailey MJ, Bellomo R, Bagshaw SM. Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial. PLoS Med. 2013;10(4):e1001426. doi: 10.1371/journal.pmed.1001426. Epub 2013 Apr 16.'}, {'pmid': '23062413', 'type': 'DERIVED', 'citation': 'Haase-Fielitz A, Plass M, Kuppe H, Hetzer R, Ostland V, Westphal S, Hoffmann J, Prowle J, Mertens PR, Westerman M, Bellomo R, Haase M. Low preoperative hepcidin concentration as a risk factor for mortality after cardiac surgery: a pilot study. J Thorac Cardiovasc Surg. 2013 May;145(5):1380-6. doi: 10.1016/j.jtcvs.2012.09.003. Epub 2012 Oct 9.'}, {'pmid': '21816077', 'type': 'DERIVED', 'citation': 'Haase-Fielitz A, Mertens PR, Plass M, Kuppe H, Hetzer R, Westerman M, Ostland V, Prowle JR, Bellomo R, Haase M. Urine hepcidin has additive value in ruling out cardiopulmonary bypass-associated acute kidney injury: an observational cohort study. Crit Care. 2011 Aug 4;15(4):R186. doi: 10.1186/cc10339.'}]}, 'descriptionModule': {'briefSummary': 'With over one million operations a year, cardiac surgery with cardiopulmonary bypass is one of the most common major surgical procedures worldwide (1). Acute kidney injury is a common and serious postoperative complication of cardiopulmonary bypass and may affect 25% to 50% of patients (2-4). Acute kidney injury carries significant costs (4) and is independently associated with increased morbidity and mortality (2,3). Even minimal increments in plasma creatinine are associated with an increase in mortality (5,6).\n\nMultiple causes of cardiopulmonary bypass-associated acute kidney injury have been proposed, including ischemia-reperfusion, generation of reactive oxygen species, hemolysis and activation of inflammatory pathways (7-10). COMT LL genotype appears to increase the risk of vasodilatory shock and AKI after cardiac surgery. To date, no simple, safe and effective intervention to prevent cardiopulmonary bypass-associated acute kidney injury in a broad patient population has been found (11-14).\n\nUrinary acidity may enhance the generation and toxicity of reactive oxygen species induced by cardiopulmonary bypass (10,15). Activation of complement during cardiac surgery (16) may also participate in kidney injury. Urinary alkalinization may protect from kidney injury induced by oxidant substances, iron-mediated free radical pathways, complement activation and tubular hemoglobin cast formation (9,17,18). Of note, increasing urinary pH - in combination with N-acetylcysteine (19,20) or without (21) - has recently been reported to attenuate acute kidney injury in patients undergoing contrast-media infusion.\n\nIn a pilot double-blind, randomized controlled trial the investigators found sodium bicarbonate to be efficacious, safe, inexpensive and easy to administer. These findings now need to be confirmed or refuted by further clinical investigations in other geographic and institutional settings.\n\nAccordingly, the investigators hypothesized that urinary alkalinization might protect kidney function in patients at increased risk of acute kidney injury undergoing cardiopulmonary bypass needs to be confirmed in an international multicenter, double-blind, randomized controlled trial of intravenous sodium bicarbonate.', 'detailedDescription': "Renal impairment following cardiopulmonary bypass is common. While most of these patients do not require either short or long term renal replacement, the mortality of patients with acute renal failure is substantially greater than those who do not develop renal dysfunction.\n\nIn a pilot double-blind, randomized controlled trial we found sodium bicarbonate to be efficacious, safe, inexpensive and easy to administer. These findings now need to be confirmed or refuted by further clinical investigations in other geographic and institutional settings.\n\nThere is evidence that sodium bicarbonate affects the cardiovascular, respiratory and immune systems and may be of benefit to patients undergoing cardiac surgery.\n\nStudy Design - overview and rationale Patients will be randomised to receive sodium bicarbonate from the induction of anaesthesia until 24 hours postoperatively, or a placebo (sodium chloride).\n\nSerum creatinine is the most commonly used clinical indicator of renal function along with urine output. Both will be measured for several days postoperatively - the time period during which renal impairment is most likely to develop.\n\nRandomisation The randomisation will be based on random numbers generated by computer. Once consent is obtained, the allocation of either treatment with sodium bicarbonate or placebo will be organised by an independent person (clinical trials pharmacist) who will dispense the coded and blinded infusion bags (shrink-wrapped in extra black plastic bags). This will be delivered to the anaesthetic staff looking after the patient in theatre, and the ICU nurse caring for the patient postoperatively.\n\n20 ml samples of heparinised blood and urine will be taken from the arterial line or urine catheter. Samples will be taken immediately after the preoperative insertion of the arterial/urine catheter, at 6, 24, 48, 72, 96 and 120 hours after commencement of cardiopulmonary bypass. Immediately following collection, the preoperative, 6 and 24 hour blood and urine will be centrifuged at low speed to separate the plasma from the cellular components. Urine and plasma and full-blood (for COMT polymorphism) will be stored in aliquots (where necessary) at -70 degrees prior to batch analysis.\n\nThe following variables will be obtained:\n\nCode for patient, gender and age. Date and time of admission to ICU Operative procedure and date and time on and off cardiopulmonary bypass Preoperative assessment of left ventricular function, Comorbidities, Pre-, intra- and post-operative medication, Markers of renal function and COMT polymorphism as described above, Doses of frusemide administered (or rate of frusemide infusion) Use of inotropes or vasopressors Cardiac output whenever measured for clinical purposes in the first 24 hours postoperatively Requirement of renal replacement therapy Urine output in each 6 hour period during the presence of urine catheter Acid base status and electrolytes at baseline, 6 and 24 hours after commencement of cardiopulmonary bypass, Time of intubation and extubation, Date and time of arrival on and discharge from ICU and hospital, death Resources required The principle of the study has been discussed with the involved cardiac anaesthetists, cardiac surgeons, intensivists and intensive care nurses, who have offered their co-operation. ICU research nurse to allocate patients and collect clinical data. Pharmacy will be required to prepare drug and placebo infusion bags. Clinical pathology will be required to perform 24 hour creatinine clearance estimation (in addition to those tests clinically indicated) Protocol violations All protocol violations will be recorded. It will then be decided whether the nature of such violation had been such that the patient should be excluded from primary data analysis. Such evaluation will be blinded to treatment.\n\nWithdrawal The treating clinician will have the right to withdraw the patient from the study if he or she believes that continued participation is jeopardising the patient's well being.\n\nEthical Issues sodium bicarbonate used in this study is considered to be very safe as has been demonstrated by its widespread clinical use in the management of critically ill patients with metabolic acidosis. We consider the potential benefit of this treatment theoretically significant. Given the balance of benefits and risks, we consider it ethical to proceed and seek informed consent.\n\nIndemnity This is an investigator-initiated study and, accordingly, no commercial sponsor's indemnity has been provided.\n\nInformed consent will be obtained from the patient prior to the operation by one of the investigators or the ICU research nurse. The clinical care of a patient who does not consent for any reason will not be affected."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Cardiac surgical patients in whom the use of cardiopulmonary bypass was planned and:\n* Written informed consent of patient\n* Age \\>18 years\n* And having at least one ore more of the following risk factors for postoperative AKI:\n\n * Age =/\\>70 years\n * Preoperative plasma creatinine \\>120 µmol/L New York Heart Association class III / IV or LVEF \\<35%\n * Insulin dependent diabetes mellitus\n * Valve surgery (with or without coronary artery bypass graft)\n * Redo cardiac surgery\n\nExclusion Criteria:\n\n* Cardiac surgical patients will not be considered eligible if:\n* An emergency operation is indicated (within 24 hours after hospital admission or on intra-aortic balloon pump) or\n* Pregnancy is confirmed or breastfeeding is present or\n* A renal allograft is present or\n* Preoperative acute renal failure within 6 weeks (acute rise in serum creatinine \\>50% from baseline) is present or\n* Pre-operative end stage renal disease (serum creatinine \\>300 µmol/L) is present or\n* Chronic moderate to high dose corticosteroid therapy (\\>10 mg/d prednisone or equivalent) is present'}, 'identificationModule': {'nctId': 'NCT00672334', 'acronym': 'Bic-MC', 'briefTitle': 'Sodium Bicarbonate in Cardiac Surgery Study', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Austin Health'}, 'officialTitle': 'A Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Sodium Bicarbonate on Postoperative Renal Function in Patients Undergoing Elective Cardiopulmonary Bypass', 'orgStudyIdInfo': {'id': 'EudraCT 2007-002223-32'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': '2', 'description': 'sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day', 'interventionNames': ['Drug: Sodium Chloride']}, {'type': 'EXPERIMENTAL', 'label': '1', 'description': 'The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction', 'interventionNames': ['Drug: Sodium Bicarbonate']}], 'interventions': [{'name': 'Sodium Bicarbonate', 'type': 'DRUG', 'otherNames': ['Hypertonic bicarbonate'], 'description': 'In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).', 'armGroupLabels': ['1']}, {'name': 'Sodium Chloride', 'type': 'DRUG', 'otherNames': ['hyeprtonic sodium chloride'], 'description': 'In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).', 'armGroupLabels': ['2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '3084', 'city': 'Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Austin Health', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': 'T6G 2B7', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'University of Alberta', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': '13353', 'city': 'Berlin', 'state': 'State of Berlin', 'country': 'Germany', 'facility': 'Charité University Medicine', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Dublin', 'state': 'Dublin', 'country': 'Ireland', 'facility': 'University Clinic Dublin, School of Medicine and Medical Science', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}], 'overallOfficials': [{'name': 'Rinaldo Bellomo, MD, FRACP', 'role': 'STUDY_CHAIR', 'affiliation': 'Austin Health, Melbourne, Australia'}, {'name': 'Michael Haase, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Charité-University Medicine (Berlin, Germany)'}, {'name': 'Sean M Bagshaw, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Alberta, Edmonton, Canada'}, {'name': 'Patrick Murray, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Clinic Dublin, Dublin, Ireland'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Austin Health', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Director of ICU research', 'investigatorFullName': 'Rinaldo Bellomo', 'investigatorAffiliation': 'Austin Health'}}}}